OPRL1-Targeted Drug Discovery Services

Introduction

The nociceptin opioid peptide receptor (NOP) is also known as the nociceptin/orphanin FQ (N/OFQ) receptor or kappa-type 3 opioid receptor. It is encoded by the OPRL1 gene. The protein encoded by this gene is a member of the 7 transmembrane-spanning G protein-coupled receptor family, and functions as a receptor for the endogenous, opioid-related neuropeptide, nociceptin/orphanin FQ. This receptor-ligand system modulates a variety of biological functions and neurobehavior, including stress responses and anxiety behavior, learning and memory, locomotor activity, and inflammatory and immune responses. A promoter region between this gene and the 5'-adjacent RGS19 (regulator of G-protein signaling 19) gene on the opposite strand functions bi-directionally as a core-promoter for both genes, suggesting co-operative transcriptional regulation of these two functionally related genes. Alternatively spliced transcript variants have been described for this gene. A recent study provided evidence for translational readthrough in this gene, and expression of an additional C-terminally extended isoform via the use of an alternative in-frame translation termination codon. [provided by RefSeq, Dec 2017]

Direction of Drugs Discovery

• OPRL1 Antagonist
• OPRL1 Modulator
• OPRL1 Inhibitor
• OPRL1 Agonist
• OPRL1 Binder
• Developing New Clinical Effects on OPRL1 from Existing Drugs

Drugs

• OPRL1 Antagonist- Banyu Compound-24, peptide III-BTD, BTRX-246040, JTC-801
• OPRL1 Modulator- LY-2940094
• OPRL1 Inhibitor- NOCICEPTIN, PMX-53, 1-benzhydryl-4-hexylpiperidin-4-ol
• OPRL1 Agonist- N/OFQ-(1-13)-NH2, SCH-221510, ND1251, SER-100
• OPRL1 Binder- SR-14136

What We Offer

Target Testing

CD BioSciences provides OPRL1 testing services by WB or IHC assay. The results of OPRL1 testing are used to evaluate the activities of candidates against OPRL1 or targeted diseases. You can choose one or more testing ways to detect the level of OPRL1 according to your experiment.

Hit Identification (show more)

The goal of early drug discovery is to find novel lead compounds that have the desired potency, selectivity, and ADMET properties for pre-clinical evaluation.
CD BioSciences offers hit identification services to make your finding of targeted compounds more successful and faster.
• High-Throughput Screening
•OPRL1-Targeted in Silico Virtual Screening
• Fragment-Based Screening
• High-Content Screening

Antibody Drugs Development Services (show more)

Antibody drugs exhibit many incomparable advantages, such as high specificity, affinity, and efficiency, which is an emerging direction on targeted drug development. CD BioSciences provides comprehensive services on OPRL1-targeted antibody drugs development with professional technology, extensive experience, and advanced equipment.
• Antibody Preparation Services
• Phage Display Services
• Antibody-Drug Conjugates
• Bispecific Antibody Services
• Antibody Humanization Services

Pharmacological Experiments (show more)

We will create a specific experimental plan according to your requirements, including but not limited to
• Pharmacokinetics / Pharmacodynamics
• Pharmacodynamics
• Pharmacokinetics
• Safety Pharmacology

Disease Models Screening (show more)

We will create specific disease models to accelerate your targeted drug discovery project, including but not limited to
• Diseases—Atopic eczema, depression, heart failure, headache, etc.
CD BioSciences will establish the specific disease models according to your requirements to evaluate the inhibitory activity of your candidates targeted OPRL1. We have various cell lines and the species of our animal models cover rats, mice, rabbits, dogs, and non-human primates.

Inquire Us

References

1. Stelzer G.; et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analysis , Current Protocols in Bioinformatics(2016), 54:1.30.1 - 1.30.33.doi: 10.1002 / cpbi.5.
2. Wishart DS; et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue): D901-6.
3. Y. Zhou; et al. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Research. 50(D1): 1398-1407 (2022). PMID: 34718870.